Dr. Thomas Wiser's lecture addresses the critical considerations for performing dental implant surgery in "compromised patients," emphasizing that an aging population and complex medication profiles necessitate a thorough, interdisciplinary approach. The core takeaway is the shift from viewing systemic disorders as absolute contraindications to making individualized risk-chance assessments based on the stability and control level of the patient's general health. The presentation details the influence of various common medications (like PPIs, SSRIs, and anti-hypertensives) on implant success rates. A significant portion focuses on anti-resorptive medications (bisphosphonates and denosumab), warning of the profound, long-term risk of medication-related osteonecrosis of the jaw (MRONJ). Wiser stresses that patients on these drugs, particularly denosumab, should be treated indefinitely as high-risk cases, requiring specialized, conservative surgical techniques, intensive prophylactic antibiotic coverage, and mandatory strict recall protocols to mitigate complications and avoid legal repercussions.
Implants in Compromised Patients: Key Considerations and Protocols
0:48 Risk Assessment through Anamnesis: Oral surgical interventions carry a complication risk exceeding 5.5%. A thorough anamnesis (patient history and medication review) is crucial for risk calculation and often requires an interdisciplinary approach with the patient's physician.
2:25 Demographic Reality: Due to increasing life expectancy, nearly every second patient presents with a general health problem, and almost every third patient takes regular drugs.
3:12 Medication Risks and Legal Consequences: Up to 16,000 deaths annually in Germany are attributed to medication mistakes or side effects. Dentistry is highlighted as having one of the highest rates of proven treatment mistakes (70%) in German medicine.
5:29 Defining the Risk Patient: A risk patient has disorders that prevent following standard protocols or negatively influence the implant success rate. However, implant placement is possible if the patient's general health status is stabilized.
7:01 Control Level is Key: The control level of the general disorder is more important than the disorder itself. Implantology should move from absolute contraindications to an individualized risk-chance assessment.
8:09 Temporary Contraindications: Absolute contraindications (e.g., fresh heart attack, epoplexy) are usually temporary, requiring a wait time of approximately six months. Surprisingly, cardiovascular diseases and obesity show no significant difference in implant survival rates.
Positive: Anti-hypertensive therapy is associated with a higher implant success rate due to a positive effect on calcium levels.
Negative: Proton Pump Inhibitors (PPIs, worldwide most prescribed) and Selective Serotonin Reuptake Inhibitors (SSRIs) increase the risk of implant failure due to a negative influence on calcium levels/bone metabolism.
12:58 Age and Implants: Age is not an absolute contraindication if the patient is stabilized. The chronological age is less important than the biological age. In older patients, non-removable or removable restorations are viable, requiring treatment strategies adapted to the patient’s physical and psychological needs.
16:25 Immediate Loading Protocol: Immediate implant loading is a standard, time-saving strategy in edentulous mandibles for older patients, provided criteria are met (implants covered fully by bone, insertion torque of 30-35 Ncm, and ISQ > 60).
22:21 Oral Hygiene in the Elderly: Bedridden patients with insufficient oral hygiene should not wear their prostheses at night to prevent aspiration pneumonia, a leading cause of death in those over 65.
23:40 Osteoporosis and Vitamin D: Osteoporosis (excluding anti-resorptive drug use) is not an absolute contraindication, resulting in a 10-year survival rate of 92%. Low Vitamin D3 levels (target 50–125) might negatively influence wound healing and implant outcome, suggesting pre-operative supplementation if deficient.
26:36 Soft Bone Management: In soft, osteoporotic bone, surgical modification is recommended, involving bone condensing instruments, smaller cavity preparation, and using compression implants to ensure good primary stability.
28:52 Smoking Risks: Smoking reduces bone quality, primarily affecting secondary stability. Intensive smokers (>20 cigarettes/day) face complication risks up to 30%. Intensive legal clearing up is mandatory.
30:26 Anti-resorptive Medications (Bisphosphonates/Denosumab): These drugs pose a high risk of Medication-Related Osteonecrosis of the Jaw (MRONJ).
Bisphosphonates: Have an extremely long half-life (over 10 years). Necrosis risk increases one to two years after starting the medication.
Denosumab (Prolia/Xgeva): Has a short half-life (one month), but the patient becomes a high-risk case immediately after the first injection. The speaker recommends treating patients who take Denosumab as risk patients for their whole life, even after stopping the drug.
36:16 MRONJ Surgical Protocol: If a patient is taking anti-resorptive medications, implants should only be placed if there is active bleeding coming out of the cavity, indicating active bone circulation. Work must be careful, using new drills and single drilling, avoiding augmentation.
37:54 MRONJ Treatment: Complications like MRONJ require advanced techniques (e.g., utilizing a tongue flap to close defects) rather than simple local flaps.
43:14 Risk Stratification: Risk profiles (High, Middle, Low) guide treatment planning, based on the type of medication (nitrogen-sustaining are higher risk), application route (IV is higher risk), duration (>6 years is higher risk), and underlying disease (cancer is higher risk).
46:10 Conservative High-Risk Treatment: When treating high-risk patients (e.g., navigations, mini implants) avoid augmentation, cover the patient with antibiotics (starting 1-3 days pre-op), and ensure complete soft tissue closure over the bone.